Vimarsana
Biggest News Aggregation in the World

Page 4 - Nasdaq Vxrt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Vxrt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Vxrt Today - Breaking & Trending Today

Critical Survey: Vaxart (NASDAQ:VXRT) versus Surface Oncology (NASDAQ:SURF) - Vimarsana News

Critical Survey: Vaxart (NASDAQ:VXRT) versus Surface Oncology (NASDAQ:SURF)

Vaxart (NASDAQ:VXRT – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Risk & Volatility Vaxart has a beta of 0.67, indicating […]

Analysts Anticipate Vaxart, Inc. (NASDAQ:VXRT) Will Post Quarterly Sales of $100,000.00 - Vimarsana News

Analysts Anticipate Vaxart, Inc. (NASDAQ:VXRT) Will Post Quarterly Sales of $100,000.00

Equities research analysts predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will post sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Vaxart’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $100,000.00. Vaxart reported sales of $110,000.00 […]

Vaxart, Inc. (NASDAQ:VXRT) Expected to Post Earnings of -$0.20 Per Share - Vimarsana News

Vaxart, Inc. (NASDAQ:VXRT) Expected to Post Earnings of -$0.20 Per Share

Wall Street brokerages predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will report ($0.20) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Vaxart posted earnings per share […]

Vaxart Announces the Publication of Studies in the - Vimarsana News

Vaxart Announces the Publication of Studies in the

A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in...

Vaxart (NASDAQ:VXRT) versus Relay Therapeutics (NASDAQ:RLAY) Critical Contrast - Vimarsana News

Vaxart (NASDAQ:VXRT) versus Relay Therapeutics (NASDAQ:RLAY) Critical Contrast

Vaxart (NASDAQ:VXRT – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Volatility and Risk Vaxart has a beta of 0.41, indicating that […]